ptc therapeutics - PTCT
PTCT
Close Chg Chg %
72.36 2.32 3.21%
Closed Market
74.68
+2.32 (3.21%)
Volume: 1.04M
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: ptc therapeutics - PTCT
PTCT Key Data
| Open $73.26 | Day Range 72.64 - 74.96 |
| 52 Week Range 35.95 - 87.50 | Market Cap $5.93B |
| Shares Outstanding 80.29M | Public Float 76.99M |
| Beta 0.48 | Rev. Per Employee N/A |
| P/E Ratio 8.46 | EPS $9.61 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.30M |
PTCT Performance
| 1 Week | -1.13% | ||
| 1 Month | -3.68% | ||
| 3 Months | 4.04% | ||
| 1 Year | 50.96% | ||
| 5 Years | 17.51% |
PTCT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
15
Full Ratings ➔
About ptc therapeutics - PTCT
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
PTCT At a Glance
PTC Therapeutics, Inc.
500 Warren Corporate Center Drive
Warren, New Jersey 07059
| Phone | 1-908-222-7000 | Revenue | 806.78M | |
| Industry | Pharmaceuticals: Major | Net Income | -363,295,000.00 | |
| Sector | Health Technology | Employees | 939 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PTCT Valuation
| P/E Current | 8.458 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.30 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -38.242 |
| Enterprise Value to Sales | 3.369 |
| Total Debt to Enterprise Value | 0.143 |
PTCT Efficiency
| Revenue/Employee | 859,190.628 |
| Income Per Employee | -386,895.634 |
| Receivables Turnover | 5.088 |
| Total Asset Turnover | 0.446 |
PTCT Liquidity
| Current Ratio | 2.35 |
| Quick Ratio | 2.31 |
| Cash Ratio | 1.962 |
PTCT Profitability
| Gross Margin | 85.357 |
| Operating Margin | -18.189 |
| Pretax Margin | -45.008 |
| Net Margin | -45.03 |
| Return on Assets | -20.072 |
| Return on Equity | N/A |
| Return on Total Capital | 51.257 |
| Return on Invested Capital | N/A |
PTCT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -54.925 |
| Total Debt to Total Assets | 22.676 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -53.04 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ptc Therapeutics - PTCT
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 538.59M | 698.80M | 937.82M | 806.78M | |
Sales Growth
| +41.45% | +29.75% | +34.20% | -13.97% | |
Cost of Goods Sold (COGS) incl D&A
| 87.08M | 161.23M | 288.12M | 118.14M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 71.52M | 128.84M | 236.59M | 75.66M | |
Depreciation
| 16.77M | 12.28M | 13.96M | 14.93M | |
Amortization of Intangibles
| 54.75M | 116.55M | 222.63M | 60.74M | |
COGS Growth
| +55.96% | +85.16% | +78.70% | -59.00% | |
Gross Income
| 451.51M | 537.57M | 649.70M | 688.64M | |
Gross Income Growth
| +38.96% | +19.06% | +20.86% | +5.99% | |
Gross Profit Margin
| +83.83% | +76.93% | +69.28% | +85.36% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 826.46M | 977.49M | 999.10M | 835.39M | |
Research & Development
| 540.68M | 651.50M | 666.56M | 534.48M | |
Other SG&A
| 285.77M | 326.00M | 332.54M | 300.91M | |
SGA Growth
| +31.73% | +18.28% | +2.21% | -16.39% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 12.21M | 24.72M | 227.66M | 155.82M | |
EBIT after Unusual Expense
| (387.15M) | (464.64M) | (577.06M) | (302.57M) | |
Non Operating Income/Expense
| (45.17M) | (31.98M) | 10.13M | 106.44M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 86.02M | 90.87M | 129.18M | 166.99M | |
Interest Expense Growth
| +52.65% | +5.64% | +42.16% | +29.27% | |
Gross Interest Expense
| 86.02M | 90.87M | 129.18M | 166.99M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (518.34M) | (587.49M) | (696.11M) | (363.12M) | |
Pretax Income Growth
| -28.64% | -13.34% | -18.49% | +47.84% | |
Pretax Margin
| -96.24% | -84.07% | -74.23% | -45.01% | |
Income Tax
| 5.56M | (28.47M) | (69.51M) | 176.00K | |
Income Tax - Current - Domestic
| 3.84M | 4.22M | (27.23M) | 46.22M | |
Income Tax - Current - Foreign
| 1.34M | 1.58M | 4.00M | 8.90M | |
Income Tax - Deferred - Domestic
| 377.00K | (34.28M) | (46.93M) | (55.91M) | |
Income Tax - Deferred - Foreign
| - | - | 646.00K | 971.00K | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (523.90M) | (559.02M) | (626.60M) | (363.30M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (523.90M) | (559.02M) | (626.60M) | (363.30M) | |
Net Income Growth
| -19.57% | -6.70% | -12.09% | +42.02% | |
Net Margin Growth
| -97.27% | -80.00% | -66.81% | -45.03% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (523.90M) | (559.02M) | (626.60M) | (363.30M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (523.90M) | (559.02M) | (626.60M) | (363.30M) | |
EPS (Basic)
| -7.4348 | -7.7935 | -8.3728 | -4.7276 | |
EPS (Basic) Growth
| -12.04% | -4.82% | -7.43% | +43.54% | |
Basic Shares Outstanding
| 70.47M | 71.73M | 74.84M | 76.85M | |
EPS (Diluted)
| -7.4348 | -7.7935 | -8.3728 | -4.7276 | |
EPS (Diluted) Growth
| -12.04% | -4.82% | -7.43% | +43.54% | |
Diluted Shares Outstanding
| 70.47M | 71.73M | 74.84M | 76.85M | |
EBITDA
| (303.42M) | (311.09M) | (112.81M) | (71.08M) | |
EBITDA Growth
| -19.98% | -2.53% | +63.74% | +36.99% | |
EBITDA Margin
| -56.34% | -44.52% | -12.03% | -8.81% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 88.429 | |
| Number of Ratings | 15 | Current Quarters Estimate | -0.502 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -1.071 | |
| Last Quarter’s Earnings | -0.197 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 9.635 | Next Fiscal Year Estimate | 0.884 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 10 | 14 | 11 |
| Mean Estimate | -0.50 | -0.30 | -1.07 | 0.88 |
| High Estimates | -0.16 | 0.15 | 0.81 | 4.22 |
| Low Estimate | -1.14 | -0.95 | -3.48 | -4.63 |
| Coefficient of Variance | -71.87 | -113.98 | -139.99 | 290.68 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 2 | 2 | 1 |
| HOLD | 4 | 4 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Ptc Therapeutics - PTCT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ptc Therapeutics - PTCT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 20, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | 105,830 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $25.69 per share | 2,718,772.70 |
| May 20, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | 103,901 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $46.18 per share | 4,798,148.18 |
| May 20, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | 104,784 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $25.69 per share | 2,691,900.96 |
| May 20, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | 103,901 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $46.02 per share | 4,781,524.02 |
| May 20, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | 28,595 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Mark Elliott Boulding EXEC. VP AND CLO | 27,712 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | 75,997 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $46.95 per share | 3,568,059.15 |
| Mar 7, 2025 | Allan Steven Jacobson Director | 19,118 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $51.52 per share | 984,959.36 |
| Feb 24, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | 5,941 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.1 per share | 297,644.10 |
| Feb 24, 2025 | Pierre Gravier CHIEF FINANCIAL OFFICER | 74,436 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.12 per share | 3,730,732.32 |
| Feb 24, 2025 | Pierre Gravier CHIEF FINANCIAL OFFICER | 75,603 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.1 per share | 3,787,710.30 |
| Feb 24, 2025 | Christine Utter SVP, CHIEF ACCOUNTING OFFICER | 62,564 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.12 per share | 3,135,707.68 |
| Feb 24, 2025 | Christine Utter SVP, CHIEF ACCOUNTING OFFICER | 63,442 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.1 per share | 3,178,444.20 |
| Feb 24, 2025 | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | 76,894 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.12 per share | 3,853,927.28 |
| Feb 24, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER; Director | 276,038 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.12 per share | 13,835,024.56 |
| Feb 24, 2025 | Matthew B. Klein CHIEF EXECUTIVE OFFICER; Director | 279,933 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.1 per share | 14,024,643.30 |
| Feb 24, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | 5,907 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.12 per share | 296,058.84 |
| Feb 24, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | 100,353 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.12 per share | 5,029,692.36 |
| Feb 24, 2025 | Eric Pauwels CHIEF EXECUTIVE OFFICER | 85,427 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.1 per share | 4,279,892.70 |
| Feb 24, 2025 | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | 101,931 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.1 per share | 5,106,743.10 |